BioLine Rx (XTAE:BLRX) Debt-to-Equity : 0.88 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Debt-to-Equity?

BioLine Rx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪13.80 Mil. BioLine Rx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪29.74 Mil. BioLine Rx's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₪49.66 Mil. BioLine Rx's debt to equity for the quarter that ended in Dec. 2023 was 0.88.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioLine Rx's Debt-to-Equity or its related term are showing as below:

XTAE:BLRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.21 Max: 0.88
Current: 0.88

During the past 13 years, the highest Debt-to-Equity Ratio of BioLine Rx was 0.88. The lowest was 0.01. And the median was 0.21.

XTAE:BLRX's Debt-to-Equity is ranked worse than
85.14% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs XTAE:BLRX: 0.88

BioLine Rx Debt-to-Equity Historical Data

The historical data trend for BioLine Rx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Debt-to-Equity Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.31

0.35

0.07

0.24

0.88

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.24	0.33	0.64	1.01	0.88

Competitive Comparison of BioLine Rx's Debt-to-Equity

For the Biotechnology subindustry, BioLine Rx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Debt-to-Equity falls into.

BioLine Rx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioLine Rx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(13.795	+	29.739)	/	49.664
	=	0.88

BioLine Rx's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(13.795	+	29.739)	/	49.664
	=	0.88

BioLine Rx (XTAE:BLRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioLine Rx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.